Neuropathological biomarker candidates in brain tumors: Key issues for translational efficiency

Clinical Neuropathology

Volumn 29, Issue 1, 2010, Pages 41-54

  Hainfellner, Johannes A ^a   Heinzl, H ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Biomarker; Brain tumor; Neuropathology; Translation

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; ONCOPROTEIN; PROTEIN INI1; TUMOR MARKER; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BRAIN TUMOR; CANCER GRADING; CANCER RECURRENCE; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME 22Q; DNA METHYLATION; FUNDING; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL RESEARCH; MENINGIOMA; METHODOLOGY; NEUROPATHOLOGY; OLIGODENDROGLIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 73649129922     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/NPP29041     Document Type: Article

References (61)

1. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin M, Whelan S (eds). International classification of diseases for oncology - 3rd edition. Geneva: World Health Organization; 2000.
2. Louis DN, Ohgaki H, Wiestler D, Cavanee WK (eds). WHO classification of tumors of the central nervous system. Lyon; IARC Press; 2007.
3. Louis DN, Ohgaki H, Wiestler D, Cavanee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol. 2007; 114: 97-109.
4. Wöhrer A, Waldhör T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mösenbacher U, Kiefer A, Maier H, Motz R, Reiner-Concin A, Richling B, Idriceanu C, Scarpatetti M, Sedivy R, Bankl H-C, Stiglbauer W, Preusser M, Rössler K, Hainfellner JA. The Austrian Brain Tumor Registry: a cooperative way to establish a population-based brain tumor registry. Journal Neurooncol. 2009; 95: 401-411.
5. CBTRUS (ed). Statistical report: primary brain tumors in the United States, 2000 - 2004. Published by the Central Brain Tumor Registry of the United States available at http://www.cbtrus.org/ reports//2007-2008/2007report.pdf.
6. Berger MS, Prados MD (eds). Textbook of Neurooncology. Philadelphia: Elsevier Saunders; 2005.
7. McGirt MJ, Chaichana KL, Attenello FJ, Weingart JD, Than K, Burger PC, Olivi A, Brem H, Quinones-Hinojosa A. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008; 63: 700-707.
8. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008; 62: 753-764.
9. van den Bent MJ, Kros JM. Predictive and Prognostic Markers in Neuro-Oncology. J Neuropathol Exp Neurol. 2007; 66: 1074-1081.
10. Yip S, Iafrate AJ, Louis DN. Molecular Diagnostic Testing in Malignant Gliomas: APractical Update on Predictive Markers. J Neuropathol Exp Neurol. 2008; 67: 1-15.
11. Fattet S, Haberler C, Legoix P, Varlet P, Lellouch-Tubiana A, Lair S, Manie E, Raquin MA, Bours D, Carpentier S, Barillot E, Grill J, Doz F, Puget S, Janoueix-Lerosey I, Delattre O. Beta-catenin status in pediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol. 2009; 218: 86-94.
12. Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, Collins VP. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008; 68: 8673-8677.
13. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360: 765-773.
14. Riemenschneider MJ, Reifenberger G. Molecular neuropathology of gliomas. Int J Mol Sci. 2009; 10: 184-212.
15. Haberler C, Laggner U, Slavc I, Czech T, Ambros IM, Ambros PF, Budka H, Hainfellner JA. Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: Lack of INI1 in atypical teratoid/ rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype. Am J Surg Pathol. 2006; 30: 1462-1468.
16. Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Wen PY, Fine HA, Mehta MP, DeAngelis LM, Lieberman FS, Cloughesy TF, Robins HI, Abrey LE, Prados MD. Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro-oncol. 2008; 10: 631-642.
17. Bast RC Jr, Lilja H, Urban N, Rimm DL, Fritsche H, Gray J, Veltri R, Klee G, Allen A, Kim N, Gutman S, Rubin MA, Hruszkewycz A. Translational crossroads for biomarkers. Clin Cancer Res. 2005; 11: 6103-6108.
18. Hinestrosa MC, Dickersin K, Klein P, Mayer M, Noss K, Slamon D, Sledge G, Visco FM. Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nat Rev Cancer. 2007; 7: 309-315.
19. Gutman S, Kessler LG. The US Food and Drug Administration perspective on cancer biomarker development. Nat Rev Cancer. 2006; 6: 565-571.
20. Preusser M, Janzer RC, Felsberg J, Reifenberger G, Hamou MF, Diserens AC, Stupp R, Gorlia T, Marosi C, Heinzl H, Hainfellner JA, Hegi M. Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol. 2008; 18: 520-532.
21. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer. 2005; 41: 1690-1696.
22. Buyse M. Towards validation of statistically reliable biomarkers. Eur J Cancer Suppl. 2007; 5: S89-S95.
23. Greenfield JP, Jin DK, Young LM, Christos PJ, Abrey L, Rafii S, Gutin PH. Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme. Neurosurgery. 2009; 64: 819-826.
24. Kros JM, Gorlia T, Kouwenhoven MC, Zheng PP, Collins VP, Figarella-Branger D, Giangaspero F, Giannini C, Mokhtari K, Mork SJ, Paetau A, Reifenberger G, van den Bent MJ. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol. 2007; 66: 545-551.
25. Mittler MA, Walters BC, Stopa EG. Observer reliability in histological grading of astrocytoma stereotactic biopsies. J Neurosurg. 1996; 85: 1091-1094.
26. Maier H, Ofner D, Hittmair A, Kitz K, Budka H. Classic, atypical, and anaplastic meningioma: three histopathological subtypes of clinical relevance. J Neurosurg. 1992; 77: 616-623.
27. Perry A, Stafford SL, Scheithauer BW, Suman VJ, Lohse CM. Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol. 1997; 21: 1455-1465.
28. Komori T, Scheithauer BW, Hirose T. A rosette-forming glioneuronal tumor of the fourth ventricle: infratentorial form of dysembryoplastic neuroepithelial tumor? Am J Surg Pathol. 2002; 26: 582-591.
29. Cenacchi G, Giangaspero F. Emerging tumor entities and variants of CNS neoplasms. J Neuropathol Exp Neurol. 2004; 63: 185-192.
30. Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 1999; 59: 74-79.
31. Judkins AR, Mauger J, Rorke LB, Biegel JA. Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms. Am J Surg Pathol. 2004; 28: 644-650.
32. Wolfsberger S, Fischer I, Hoftberger R, Birner P, Slavc I, Dieckmann K, Czech T, Budka H, Hainfellner J. Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma. Am J Surg Pathol. 2004; 28: 914-920.
33. Preusser M, Heinzl H, Gelpi E, Hoftberger R, Fischer I, Pipp I, Milenkovic I, Wohrer A, Popovici F, Wolfsberger S, Hainfellner JA. Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Histopathology. 2008; 53: 39-47.
34. Bello MJ, Vaquero J, de Campos JM, Kusak ME, Sarasa JL, Saez-Castresana J, Pestana A, Rey JA. Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors. Int J Cancer. 1994; 57: 172-175.
35. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol. 1994; 145: 1175-1190.
36. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998; 90: 1473-1479.
37. Chahlavi A, Kanner A, Peereboom D, Staugaitis SM, Elson P, Barnett G. Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J Neurooncol. 2003; 61: 267-273.
38. van den Bent MJ, Looijenga LHJ, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, Sillevis Smitt PA, Jenkins RB, Kros JM. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer. 2003; 97: 1276-1284.
39. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-996.
40. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 997-1003.
41. Fruehauf JP, Brem H, Brem S, Sloan A, Barger G, Huang W, Parker R. In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res. 2006; 12: 4523-4532.
42. Preusser M, Elezi L, Hainfellner JA. Reliability and reproducibility of PCR-based testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens. Clin Neuropathol. 2008; 27: 388-390.
43. Beer S. Diagnosing the system for organisations. Chichester: John Wiley & Sons; 2007.
44. Holland JH. Hidden Order: how adaptation builds complexity. New York: Helix Books (Addison Wesley); 1995.
45. World Medical Association. Declaration of Helsinki. Ethical principles formedical research involving human subjects, available at http://www.wma.net/en/30publications/10policies/b3/index.htm
46. George SL. Statistical Issues in Translational Cancer Research. Clin Cancer Res. 2008; 14: 5954-5958.
47. Halpern SD, Karlawish JHT, Berlin JA. The Continuing Unethical Conduct of Underpowered Clinical Trials. JAMA. 2002; 288: 358-362.
48. Hilsenbeck SG, Clark GM, McGuire WL. Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat. 1992; 22: 197-206.
49. Riley RD, Sauerbrei W, Altman DG.: Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer. 2009; 100: 1219-1222.
50. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer. 1994; 69: 979-985.
51. Simon RM. Guidelines for the design of clinical studies for the development and validation of therapeutically relevant biomarkers and biomarker-based classification systems. In: Gasparini G, Hayes DF (eds): Biomarkers in breast cancer: molecular diagnostics for predicting and monitoring therapeutic effect. Cancer Drug Discovery and Development. Totowa: Humana Press; 2005. p 3-15.
52. Chow SC, Liu JP. Design and analysis of clinical trials: concepts and methodologies. Hoboken: John Wiley & Sons, Inc; 2004.
53. Finn R. Cancer clinical trials: experimental treatments and how they can help you. Sebastopol: O'Reilly & Associates; 1999.
54. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical Trial Design for Predictive Marker Validation in Cancer Treatment Trials. J Clin Oncol. 2005; 23: 2020-2027.
55. Tan S-B, Dear KBG, Bruzzi P, Machin D. Strategy for randomized clinical trials in rare cancers. BMJ. 2003; 327: 47-49.
56. Axelrod R. The Evolution of Cooperation. New York: Basic Books, Inc., Publishers; 1984.
57. Rothwell PM. Medical academia is failing patients and clinicians: By neglecting basic observational clinical research. BMJ. 2006; 332: 863-864.
58. Rothwell PM. Funding for practice-oriented clinical research. The Lancet. 2006; 368: 262-266.
59. Brain Tumour Group (BTG) of the European Organization for Research and Treatment of Cancer (EORTC). web access: http://groups.eortc.be/ brain/
60. European Confederation of Neuropathological Societies. web access: http://www.euro-cns.org
61. European Confederation of Neuropathological Societies (Euro-CNS). Society News. Brain Tumour Group of EORTC. Clin Neuropathol 2009; 28: 245.